Table 3. Improvement of visual acuity with follow-up.
logMAR Gain of ≥ 0.3 | Baseline | 3 Months | 6 Months | 9 Months | 12 Months |
---|---|---|---|---|---|
Bevacizumab (%) | Reference | 9 (13.6%) | 11 (16.7%) | 13 (19.7%) | 12 (18.2%) |
Ranibizumab (%) | Reference | 10 (16.7%) | 14 (23.3%) | 13 (21.7%) | 14 (23.3%) |
Pa | 0.53 | 0.12 | 0.32 | 0.29 |
Abbreviation: logMAR, logarithm of the minimum angle of resolution.
On the basis of χ2 test.